Current Positions and Research:
Dr Muireann Coen is a Senior Lecturer in Metabonomics and Biochemical Toxicology in Biomolecular Medicine, Department of Metabolism, Digestion and Reproduction at Imperial College London. Her core research focuses on the development and application of metabolic phenotyping in the field of toxicology and pharmacology and hence she has gained extensive expertise in the fields of analytical chemistry, pharmacometabonomics, pre-clinical and clinical toxicology, xenobiotic and endogenous metabolism, cross-omics and bioinformatics, molecular epidemiology and the exposome.
Dr Coen transitioned to AstraZeneca in 2017 where she is an Associate Director, in Oncology Safety, Clinical Pharmacology & Safety Sciences. The overarching aim of her research is to further mechanistic understanding of toxicity, identify translational biomarkers and in so doing to improve both the pre-clinical drug development process and ultimately therapeutic safety and efficacy. Dr Coen is also establishing strong collaborative networks between Imperial College and AstraZeneca through Masters student projects, PhD studentships and fellowships.
In addition to Dr Coen’s academic track record she is a keen advocate of the Athena Swan initiative and a strong supporter of college outreach activities.
Dr Coen was awarded an MRC Integrative Toxicology Training Partnership (ITTP) career development fellowship (2009-2012) and continues to work closely with the MRC ITTP scheme through inter-disciplinary PhD studentships.
She is a member of the British Toxicology Society's Scientific sub-committee, MRC ITTP committee and the Royal Society of Chemistry’s Toxicology Group Committee.
Dr Coen completed her BSc in Chemistry (First Class Honours) at Kings College London followed by a PhD at Imperial under the supervision of Professor Jeremy Nicholson. She then held a Royal Society Fellowship at the University of Sydney and returned to Imperial for postdoctoral work prior to being awarded an MRC fellowship and lectureship.
et al., 2022, Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment, Archives of Toxicology, Vol:96, ISSN:0340-5761, Pages:613-624
et al., 2018, Urine metabolic signatures of multiple environmental pollutants in pregnant women - an exposome approach, Environmental Science & Technology, Vol:52, ISSN:0013-936X, Pages:13469-13480
et al., 2018, Determinants of the urinary and serum metabolome in children from six European populations, BMC Medicine, Vol:16, ISSN:1741-7015
et al., 2017, MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure, Gut, Vol:67, ISSN:1468-3288, Pages:333-347
et al., 2016, Mutlivariate metabotyping of plasma accurately predicts survival in decompensated cirrhosis, Journal of Hepatology, Vol:64, ISSN:1600-0641, Pages:1058-1067
et al., 2015, Metabolic phenotyping for enhanced mechanistic stratification of chronic Hepatitis C-Induced liver fibrosis, American Journal of Gastroenterology, Vol:110, ISSN:0002-9270, Pages:159-169
Coen M, 2014, Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity, Drug Metabolism Reviews, Vol:47, ISSN:1097-9883, Pages:29-44
et al., 2014, Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT, Journal of Hepatology, Vol:60, ISSN:0168-8278, Pages:96-102
et al., 2017, Multi-platform metabonomics reveals a distinct metabolic phenotype of acute-on-chronic liver failure, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Wiley, Pages:675A-675A, ISSN:0270-9139